Original Research Article

- 3 Association between antihypertensive combinations and postoperative mortality
- 4 and functional decline: a nationwide survey of Japanese adults undergoing major
- 5 surgeries

1

2

6

- 7 Rena Suzukawa¹, Shintaro Mandai¹*, M.D., Ph.D., Yuta Nakano¹, M.D., Shunsuke
- 8 Inaba¹, M.D., Hisazumi Matsuki¹, M.D., Yutaro Mori¹, M.D., Ph.D., Fumiaki Ando¹,
- 9 M.D., Ph.D., Takayasu Mori¹, M.D., Ph.D., Koichiro Susa¹, M.D., Ph.D., Soichiro
- 10 Iimori¹, M.D., Ph.D., Shotaro Naito¹, M.D., Ph.D., Eisei Sohara¹, M.D., Ph. D.,
- 11 Tatemitsu Rai², M.D., Ph. D., Kiyohide Fushimi³, M.D., Ph.D., Shinichi Uchida¹, M.D.,
- 12 Ph.D.

13

- ¹Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo
- 15 Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan
- ²Department of Nephrology and Hypertension, Dokkyo Medical University, 880
- 17 Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan
- 18 ³Department of Health Policy and Informatics, Graduate School of Medical and Dental
- 19 Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo
- 20 113-8519, Japan

21 22 Suzukawa R and Mandai S contributed equally. 23 24 Short title: Antihypertensive class and postoperative outcomes 25 26 *Corresponding Author: Shintaro Mandai (ORCID iD: 0000-0001-6709-306X) 27 Department of Nephrology, Graduate School of Medical and Dental Sciences, Tokyo 28 Medical and Dental University, 1-5-45 Yushima, Bunkyo, Tokyo 113-8519, Japan 29 Tel: +81-3-5803-5214; Fax: +81-3-5803-5215; E-mail: smandai.kid@tmd.ac.jp 30 31 Total word count: 3,543

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Abstract Background: Considering the limited information available regarding the impact of antihypertensive classes on mortality and physical function during hospitalization, we aimed to clarify the impact of six antihypertensive classes, namely thiazide/thiazide-like diuretics (TH), calcium receptor blockers (CCBs), renin-angiotensin-aldosterone system inhibitors (RASis), mineral corticoid receptor antagonists, α-blockers, and β-blockers, on outcomes in adult patients undergoing major surgeries. **Methods:** This study was a subanalysis of a nationwide observational cohort study involving Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database. We recruited 473,327 antihypertensive medication users and 376,583 nonusers aged ≥50 years who underwent six different types of surgeries, including coronary artery bypass grafting (CABG), thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery. The risk for overall death or functional decline, defined as a \geq 5-point decrease in the Barthel Index score during hospitalization, was determined using multivariable logistic regression models. **Results:** All-cause inhospital deaths occurred in 5,777 (1.2%) users and 2,657 (0.7%)

nonusers. Functional decline was observed in 42,930 (9.2%) users and 22,550 (6.0%)

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

What is new?

nonusers. Among single class users, RASi use had a multivariable odds ratio (OR) of 0.77 (95% confidence interval (CI) 0.63–0.93 vs. TH) for the composite of mortality and functional decline. β-Blocker use was associated with an increased risk for functional decline (OR 1.27, 95% CI 1.01-1.60 vs. TH). Among the recipients of the two medication classes, TH/RASi usage was associated with the lowest risk for composite outcome (OR 0.68, 95% CI 0.60-0.77 vs. TH/CCB). Among the recipients of the three or more medication classes, TH/CCB/RASi or TH/CCB/RASi/other displayed the lowest odds for composite outcome (OR 0.72, 95% CI 0.49–0.82 vs. TH/CCB/other; OR 0.63, 95% CI 0.49–0.82 vs. TH/CCB/others). A stratified analysis revealed that RASi users had a lower OR for the composite outcome after major surgery categories except CABG than non-RASi users. Conclusions: RASis were associated with decreased risk of postoperative mortality and functional decline regardless of the number of antihypertensive classes or surgery type. Managing hypertension through multidrug combinations, including RASis, may mitigate mortality and loss of physical function during the perioperative period. **Clinical Perspective**

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

This nationwide observational cohort study of Japanese adults undergoing major surgeries from 2018 to 2019 using an administrative claims database showed that all-cause inhospital deaths occurred in 5,777 (1.2%) antihypertensive users and 2,657 (0.7%) nonusers, whereas functional decline was observed in 42,930 (9.2%) antihypertensive users and 22,550 (6.0%) nonusers. We found that an increase in the number of antihypertensive classes used, indicative of patients with treatment-resistant hypertension, was associated with a higher risk of mortality and loss of physical function, partly attributed to loop diuretic use for congestion. What are the clinical implications? This study determined combinations of antihypertensive drugs that potentially improve the outcomes of antihypertensive users undergoing major surgeries, with the favorable regimens including RASis independent of the number of antihypertensive classes used. After undergoing all major surgery categories except CABG, patients on RASis were at a lower risk of death and functional decline than those who were treated with other antihypertensive classes.

86 **Keywords:** hypertension, antihypertensive class, surgery, physical function, 87 renin-angiotensin-aldosterone system inhibitor 88 89 **Nonstandard Abbreviations and Acronyms** 90 **ACEi** angiotensin-converting enzyme inhibitor 91 AKI acute kidney injury 92 **ADL** activities of daily living 93 AHT acute hypertension 94 ARB angiotensin II receptor blocker 95 **BMI** body mass index 96 **CABG** coronary artery bypass grafting 97 **CCB** calcium channel blocker 98 CI confidence intervals 99 **CKD** chronic kidney disease 100 **CVD** cardiovascular disease 101 DM diabetes mellitus 102 DPC diagnosis procedure combination 103 **ESKD** end-stage kidney disease 104 ICD-10 International Classification of Disease and Related Health Problems, 105 10th Revision 106 **IQR** interquartile range 107 MRA mineral corticoid receptor antagonist 108 OR odds ratio

109	RAS	renin-angiotensin system
110	RASi	renin-angiotensin-aldosterone system inhibitor
111	ROS	reactive oxygen species
112	TH	thiazide/thiazide-like diuretics
113		

Introduction

114

115

116

117

118

119

120

121

122

123

124

125

126

127

The proportion of patients with hypertension continues to increase globally. The number of adult patients with hypertension doubled from 1990 to 2019, affecting nearly 1,300 million people worldwide [1]. Although recent advances in antihypertensive medications and their widespread availability have improved hypertension control in this population, the prevalence of treatment-resistant hypertension requiring a combination of multiple antihypertensive classes has continued to increase [2-5]. When caring for patients with hypertension, the prevention of chronic systemic organ dysfunction, hospitalization, acute kidney injuries (AKI), and death caused by acute hypertension (AHT) is of considerable importance [6]. We previously reported an increase in absolute death and urgent dialysis due to AHT from 2010 to 2019 among hospitalized Japanese patients [6]. Given the lack of comprehensive investigations on the effective combination of antihypertensive classes and the mostly empiric evidence available [4], understanding the effects of various antihypertensive medications and

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

their management approaches for both in- and outpatients has been of notable interest among physicians. The decline in activities of daily living (ADLs) and frailty related to hospitalization have also been an enormous health concern for inpatients, given the exponential increase in the aging population globally. Previous studies have established that the use of angiotensin-converting enzyme inhibitors (ACEis) has long-term effects on muscle strength [7,8]. The use of angiotensin II receptor blockers (ARBs) promotes enhanced exercise capacity among patients with heart failure [9]. In contrast, our studies showed that patients taking loop diuretics were at an increased risk of developing sarcopenia [10,11], with subsequent studies reporting the same correlation among patients with heart failure and hepatopathy [12-14]. However, no study has focused on the effects of antihypertensive class or loop diuretics during hospitalization under acute care settings, i.e., in patients with severe diseases (e.g., cardiovascular diseases [CVDs], infectious diseases, or major surgeries). We evaluated the impact of continued empirical antihypertensive drug administration during hospitalization on postoperative outcomes, including mortality and physical function, after major surgeries. The current study aimed to determine the most effective monotherapy or

combination therapy among six antihypertensive classes (i.e., thiazide/thiazide-like

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

diuretics [TH], calcium receptor blockers [CCBs], renin-angiotensin-aldosterone system inhibitors [RASis], mineral corticoid receptor antagonists [MRAs], α-blockers, and β-blockers) and loop diuretics, which helps lower the risk for postoperative mortality and functional decline among patients aged 50 and older who underwent major surgeries during hospitalization. We also aimed to investigate whether the type of major surgery (i.e., coronary artery bypass grafting [CABG], thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery) altered the association between antihypertensive class and postoperative outcomes. Methods Study design and participants This study was a *posthoc* subanalysis of a national survey on postoperative outcomes among Japanese adults undergoing major surgeries [15]. We used an administrative claims database, the Diagnosis Procedure Combination (DPC) inpatient database, to obtain data from 2018 to 2019 [6,15,16]. This dataset comprises information obtained from over 1000 hospitals, including all 82 teaching hospitals, and

covers half or more of inpatient cases throughout Japan. The available information

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

included diagnosis and comorbidities upon hospital admission coded according to the International Classification of Disease and Related Health Problems, 10th Revision [14]. The datasets also included information on patients' age, sex, body mass index (BMI), the Charlson comorbidity index [17], which was updated for risk adjustment [18], ADLs upon admission and discharge, and discharge status. A total of 15,422,773 eligible cases were identified. The criteria for study inclusion included age ≥50 years, hospitalization ≥24 h, and patients undergoing any of the defined major surgeries. Major surgeries were previously defined as invasive operative procedures, including CABG, thoracic lobectomy, orthopedic surgery (hip or knee arthroplasty, laminectomy or spinal fusion, and surgery for hip fracture or dislocation), hepatopancreatobiliary surgery (hepatic lobectomy, cholecystectomy, and pancreatectomy), gastrointestinal resection (esophagectomy, gastrectomy, and colectomy), and urological surgery (cystectomy and nephrectomy) [15,19]. The exclusion criteria were as follows: second or later admissions; patients with incomplete information on BMI, the Barthel Index, and admission type (emergency admission or not); those who underwent multiple surgery types; and dependence on maintenance dialysis therapy. Dependence on hemodialysis or peritoneal dialysis was determined from the coding of patient care procedures (chronic maintenance hemodialysis with <4

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

h per session, ≥ 4 h but <5 h per session, ≥ 5 h per session or chronic maintenance hemodiafiltration or continuous peritoneal dialysis) [17]. Our study protocol was approved by the ethics committee of Tokyo Medical and Dental University. The need for informed consent was waived because the data were anonymized. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The data used for the study analyses are available from the corresponding author S.M. upon reasonable request. Patient characteristics We calculated the Barthel Index scores upon admission and discharge based on 10 functional abilities, including feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation, and climbing stairs [20]. Barthel Index scores ranged from 0 to 100 at 5-point increments, with 0 indicating complete bed-ridden status and 100 indicating full independence of physical functions. Other patient information on admission included age, sex, BMI, dependence on urgent or maintenance kidney replacement therapy, updated Charlson comorbidity index, excluding renal disease [17,18], comorbidity, surgery type, admission type (emergency or elective admission), and fiscal year. We used the following age strata for the analyses: 50-59, 60-69, 70-79, and ≥ 80 years [21]. On the basis of previous studies, antihypertensive medications were classified into six groups, including TH, CCBs, RASis, MRAs, α -blockers, and β -blockers [22, 23]. Thiazide-like diuretics without a

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

benzothiadiazide structure, such as indapamide and metolazone, were also categorized under TH. Only dihydropyridines were included as CCBs in this study. RASis included ACE is and ARBs. Notably, α/β -blockers were included under β -blockers. Loop diuretics were recognized when used both orally and intravenously. Outcomes The primary outcome was the composite of overall inhospital death and decline in physical function, which was defined as a 5-point lower Barthel Index score [24] at discharge than at admission. Patients were followed up until discharge, transfer, or inhospital death. Data analyses Data were presented as number (percentage) or median (interquartile range [IQR]). Logistic regression models were used to assess the association between antihypertensive medication and loop diuretics and the risk for mortality or functional decline, adjusting for potential confounding measurements, including age, sex, type of major surgeries, BMI, Barthel Index score upon admission, diabetes mellitus (DM), CVD, chronic kidney disease (CKD), emergency admission, and year of admission. We conducted subgroup analyses using logistic regression models to determine the

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

association between antihypertensive class and outcomes according to major surgery type. All statistical analyses were performed using Stata version 15.0 (Stata Corp., College Station, TX, United States), with P < 0.05 indicating statistical significance. **Results** Patient characteristics We identified 15,422,773 patients from a Japanese national inpatient database between 2018 and 2019 (Fig. S1). Subjects aged 50 years and older who underwent major operations during hospitalization lasting for at least 24 h were included (n = 1,283,540). Subsequently, those on their second or later admissions; those without complete information on BMI, Barthel Index score, or emergency admission; and those who underwent multiple surgeries or received maintenance dialysis were excluded. In total, 849,910 subjects were included in the analysis. Table 1 summarizes the demographics and characteristics of the study cohort. Among the 849,910 patients, 473,327 (56%) were taking at least one class of antihypertensive medication. Antihypertensive users and nonusers had a median age (IQR) of 76 (69–82) years and 70 (63–78) years, female percentage of 49% and 50%, and median BMI of 23.4 (20.9–26.0) kg/m² and 22.5 (20.2–24.9) kg/m², respectively. A

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

larger proportion of antihypertensive users than nonusers had a low Barthel Index score. The prevalence of comorbidities, including CVD, DM, and CKD, was higher among antihypertensive users than among nonusers. Patients were also stratified according to the type of major surgery that they underwent during hospitalization. Among the six types of major surgeries (CABG, thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery), orthopedic surgery was the most common in both groups (45% and 37%, respectively), followed by gastrointestinal resection and esophagectomy (20% and 25%, respectively). Effects of the number of antihypertensive classes on postoperative outcomes After a median follow-up of 17 (IQR, 10–27) days, all-cause inhospital deaths were observed in 5,777 patients (1.2%) out of 473,327 antihypertensive users and 2,657 patients (0.7%) out of 376,583 nonusers. Functional decline was observed in 22,550 (6.0%) nonusers and 42,930 (9.2%) users. Figure 1 displays the prevalence of all-cause inhospital death and functional decline after survival according to age category. The proportions of mortality and functional decline were higher among patients on more antihypertensive classes than among those on no or fewer antihypertensive classes. This

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

indicates a significant association between resistance and antihypertensive treatment and the crude mortality rate and decline in ADLs (Figure 1) Thereafter, multivariable logistic regression models were created to determine the aggregate risk for all-cause inhospital death and functional decline after survival. In the age- and sex-adjusted model, the odds ratios (ORs) for a composite outcome of mortality and functional decline were 1.20 (95% confidence interval [CI], 1.18–1.23), 1.23 (95% CI, 1.20–1.25), 1.42 (95% CI, 1.38–1.47), and 1.57 (95% CI, 1.49–1.65) for users receiving one, two, three, and four or more classes of antihypertensives when compared with nonusers (Table 2). Similarly, in Models 2 and 3, which adjusted for DM, CVD, CKD, emergency admission, and admission year, the use of more antihypertensive classes was associated with a higher risk for the composite outcome. After additionally adjusting for the use of loop diuretics (Model 4), the odds for the composite outcome were comparable between users receiving one, two, three, and four or more classes of antihypertensives. These findings indicate that congestion requiring the use of loop diuretics is a major confounding factor for the association between resistant hypertension and unfavorable postoperative outcomes.

Combinations of antihypertensive classes and postoperative outcomes

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

We then investigated whether differences in postoperative outcomes following major surgeries were present according to different combinations of antihypertensive classes among the patients. Among those who used only one of the six antihypertensive classes and loop diuretics, RASis showed the lowest OR for composite outcome, mortality, and functional decline (Table 3). With TH as the reference, RASi showed 0.77-, 0.58-, and 0.79-times lower odds for the composite outcome (95% CI, 0.63–0.93; P = 0.008), mortality (95% CI, 0.34–0.99; P = 0.045), and functional decline (95% CI, 0.64–0.96; P = 0.045) = 0.020), respectively, whereas β -blockers showed a 1.27-times higher odds for functional decline (95% CI, 1.01-1.60; P = 0.040; Table 3). Among those who used two antihypertensive classes, the combination of THs and RASi showed the lowest OR for each outcome. Compared with TH/CCB, TH and RASi had an OR of 0.68 for the composite outcome (95% CI, 0.60–0.77; P < 0.001; Table 3). Among those who used three or more classes of antihypertensive, combinations including CCB and RASi showed the lowest OR for each outcome. In comparison, using the combination of TH, CCB, and other as the reference, the combination of TH, CCB, and RASi showed odds of 0.72-, 0.43-, and 0.79-times lower for the composite outcome (95% CI, 0.49–0.82; P < 0.001), mortality (95% CI, 0.31–0.60; P < 0.001), and functional decline (95% CI,

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

0.70-0.89; P < 0.001; Table 3), respectively. The use of RASis was significantly associated with a lower OR for postoperative outcomes regardless of the number of antihypertensive classes used for treatment. A comparison of those who did and did not use loop diuretics showed that loop diuretic use consistently resulted in significantly higher ORs for the composite outcome, mortality, and functional decline regardless of the number of other antihypertensive medications used (Table S1). Impact of each antihypertensive class on postoperative outcomes according to the type of major surgery We performed a stratified analysis on the impact of each antihypertensive class on postoperative outcomes according to six types of major surgeries (CABG, thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery). Notably, RASis were associated with lower ORs for the composite outcome of death and functional decline, all-cause inhospital death, and survival with functional decline among those who underwent five types of major surgeries except CABG (Figure 2). Only β-blocker use was associated with better outcomes among patients who underwent CABG (OR, 0.77; 95% CI, 0.67–0.89).

Discussion

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

The current large-scale epidemiologic cohort study using the Japanese administrative claims database clarified the effects of antihypertensive drugs on postoperative mortality and functional decline in patients aged 50 and older. First, we found that an increase in the number of antihypertensive classes, which indicated treatment-resistant hypertension, was associated with a higher risk of mortality and loss of physical function, partly attributed to loop diuretic use needed for congestion. Second, we determined combinations of antihypertensives that potentially improve the outcomes of antihypertensive users undergoing major surgeries. The favorable regimens included RASis independent of the number of antihypertensive classes used. Third, among patients who underwent any type of major surgery, excluding CABG, those on RASis were at a lower risk of death and functional decline than those not treated with other antihypertensive classes. The primary finding of the current study was that patients who received RAS inhibition had a lower risk for the composite outcome of all-cause inhospital death and functional decline after surviving major surgeries than those without RAS inhibition, independent of the number of antihypertensive classes used. RAS inhibition in patients treated with ACEi and ARB is known to help decrease skeletal muscle loss [7-9]. A

plausible explanation for its underlying pathological mechanism is the suppression of

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

angiotensin II-induced impairment in protein synthesis, acceleration of protein breakdown, and loss of appetite. Angiotensin II increases the levels of cytokines and systemic hormones, including reactive oxygen species, insulin-like growth factor 1, tumor necrosis factor alpha, interleukin-6, and transforming growth factor beta [7-9, 24-28]. The current study showed that among patients who used a single class of antihypertensive, those who used RASi had lower odds for the composite outcome of mortality and functional decline than those who used TH. Among those who received two classes of antihypertensives, those who received a combination of TH/RASi had an OR of 0.68 for the composite outcome compared with those on TH/CCB. The favorable effects of RASis on mortality and functional decline were also observed among those who used three or more antihypertensive classes. Our data clearly showed that RAS interfered with functional decline, although pathological analysis at the molecular level was not conducted. Our findings showed that β-blocker users had a 1.27-fold higher OR for functional decline than TH users, which is consistent with previous findings on the association between β-blocker and functional decline in patients with end-stage kidney disease (ESKD) [29], CVD, and heart failure [30, 31]. In our previous study on a cohort

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

with ESKD, β-blocker users had 2.5-fold higher odds of annual skeletal muscle mass loss, whereas the use of RASi in combination with other medications minimized the adverse effects [29]. Notably, only the use of β-blockers was markedly associated with a lower risk for postoperative composite outcome in patients who underwent CABG. Therefore, the current study reaffirms the positive effects of RASi on skeletal muscle mass in acute care settings among patients undergoing major surgeries [29]. Nonetheless, further investigations are needed to uncover the mechanism underlying the association between RAS inhibition and favorable outcomes after major surgeries, excluding CABG. Our findings showed that outcomes following major surgeries could be further improved by combining empirically antihypertensive drugs prescribed. Frailty, often defined as unintentional weight loss, has been shown to be associated with mortality among inhospital patients [32], as well as postdischarge patients or outpatients [33-35]. Newly acquired functional decline among older persons owing to hospital admissions is especially serious given the already high prevalence of frailty among community-dwelling people in the aging Japanese society [36] and its association with higher mortality and economic burden. Our findings showed that 9.2% of antihypertensive drug users and 6.0% of nonusers experienced a decrease in their

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

Barthel Index score during hospitalization, a figure even higher than the 7.4% overall pooled prevalence of frailty among Japanese community-dwelling people aged 65 and older reported in a previous review [36]. This suggests that the probability of functional decline is primarily higher among inpatients and that patients with hypertension are at substantially higher risk. Thus, combinations of antihypertensive drugs, including RASis, may improve the clinical outcomes of patients with hypertension by minimizing functional decline through internal treatment during the acute phase of hospitalization. A substantial proportion of patients worldwide remain resistant to hypertension treatment and are usually treated with more antihypertensive medication classes. However, the optimal combinations of antihypertensives are yet to be fully understood. As expected, our findings showed that the number of antihypertensive classes was positively correlated with the risk of mortality and functional decline. Indeed, we found that patients on multiple antihypertensive medications were at a greater risk for the composite outcome, even after adjusting for potential confounders. Notably, after adjusting for the use of loop diuretics, the odds for the risk of the composite outcome were similar regardless of the number of antihypertensive classes used, suggesting that loop diuretic usage was a powerful confounding factor associated with mortality and functional decline. Loop diuretics are indispensable in addressing fluid retention among

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

patients with renal and heart failure. One possible side effect of loop diuretics is sarcopenia, as discussed in previous studies [10-14]. Na+-K+-2Cl- cotransporter 1, which is highly expressed in mammalian skeletal muscle and inhibited by furosemide, might help prevent muscle loss based on its background pharmacological mechanism [10]; however, the pathological pathway has yet to be not fully elucidated. One strength of the current study is that we used well-validated Japanese administrative data representing a sample of the general population. The validity of the diagnoses and procedural records in the Japanese DPC database was corroborated in a previous study [37]. However, several limitations need to be acknowledged. First, this study was exclusively conducted on a single race or ethnicity. Evidence suggests that Asian populations have a higher prevalence of uncontrolled hypertension [38]. Hence, our findings may not be generalizable to other ethnicities. Second, the use of more than one antihypertensive drug within the same antihypertensive class was under-represented in this study. Third, given the nature of the datasets used herein, we were unable to determine changes in blood pressure and antihypertensive drug use during hospitalization potentially caused by poor control, complications, or side effects. The number of antihypertensive classes may have been overestimated. Finally, the database lacked biochemical data and longitudinal outcomes after discharge. Our study focused

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

only on the effects of antihypertensive medication on postoperative mortality and functional decline during the acute phase of hospitalization following major surgeries. A previous multicenter retrospective cohort study showed that the postoperative initiation of RASis even at discharge was associated with reduced long-term mortality rate in patients undergoing cardiac surgery [39]. Randomized controlled trials are needed to determine whether perioperative RASi initiation could improve outcomes following cardiac and non-cardiac surgeries. In conclusion, the current study highlights the effects of antihypertensive classes and their combinations on the risk of postoperative mortality and functional decline. Our findings showed that RASis usage had a positive prognostic impact on postoperative inhospital death and functional decline regardless of the number of antihypertensive medication classes used. Thus, RASi use may mitigate negative postoperative outcomes after major noncardiac surgeries. Acknowledgments We would like to thank all study participants. **Sources of Funding**

419 This study was supported by the Health and Labour Sciences Research Grant (Grant No. 420 Seisaku-Sitei-22AA2003 to KF) of the Japan Ministry of Health, Labour and Welfare. 421 422 **Disclosures** 423 **Conflict of interest** 424 None. 425 426 References 427 Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, 1. 428 Gregg EW, Bennett JE, Solomon B, Singleton RK, et al. Worldwide trends in 429 hypertension prevalence and progress in treatment and control from 1990 to 2019: a 430 pooled analysis of 1201 population-representative studies with 104 million participants. 431 Lancet. 2021;398:957-980. 432 2. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, et al. Resistant 433 434 hypertension: detection, evaluation, and management: A scientific statement from the 435 American Heart Association. *Hypertension*. 2018;72:e53–e90.

- 436 3. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008.
- 437 *Hypertension*. 2011;57:1076–1080.
- 438 4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A,
- Cushman WC, White W, Sica D, et al. Resistant hypertension: diagnosis, evaluation,
- 440 and treatment. A scientific statement from the American Heart Association Professional
- 441 Education Committee of the Council for High Blood pressure research. *Hypertension*.
- 442 2008;51:1403–1419.
- 443 5. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat*
- 444 Rev Nephrol. 2020;16:223–237.
- 445 6. Matsuki H, Genma T, Mandai S, Fujiki T, Mori Y, Ando F, Mori T, Susa K,
- 446 Iimori S, Naito S, et al. National trends in mortality and urgent dialysis after acute
- hypertension in Japan from 2010 through 2019. Hypertension. 2023;80:2591–2600.
- 448 7. Dr Onder G, Penninx BWJH, Balkrishnan R, Fried LP, Chaves PH, Williamson
- J, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of
- 450 angiotensin-converting enzyme inhibitors and muscle strength and physical function in
- older women: an observational study. *Lancet*. 2002;359:926–930.
- 452 8. Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A,
- 453 Harris TB, Williamson JD, Marchionni N, Pahor M, Health, Aging and Body

- 454 Composition Study. Antihypertensive medications and differences in muscle mass in
- older persons: the health, aging and body composition study. J Am Geriatr Soc.
- 456 2004;52:961–966.
- 457 9. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G,
- Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to
- 459 maximal angiotensin-converting enzyme inhibition improves exercise capacity in
- patients with severe congestive heart failure. *Circulation*. 1999;99:990–992.
- 461 10. Mandai S, Furukawa S, Kodaka M, Hata Y, Mori T, Nomura N, Ando F, Mori Y,
- Takahashi D, Yoshizaki Y, et al. Loop diuretics affect skeletal myoblast differentiation
- and exercise-induced muscle hypertrophy. *Sci Rep.* 2017;7:46369.
- 464 11. Ishikawa S, Naito S, Iimori S, Takahashi D, Zeniya M, Sato H, Nomura N,
- Sohara E, Okado T, Uchida S, et al. Loop diuretics are associated with greater risk of
- sarcopenia in patients with nondialysis-dependent chronic kidney disease. *PLOS ONE*.
- 467 2018;13:e0192990.
- 468 12. Hanai T, Shiraki M, Miwa T, Watanabe S, Imai K, Suetsugu A, Takai K,
- 469 Moriwaki H, Shimizu M. Effect of loop diuretics on skeletal muscle depletion in
- patients with liver cirrhosis. *Hepatol Res.* 2019;49:82–95.

- 471 13. Felker GM, O'Connor CM, Braunwald E, Heart Failure Clinical Research
- Network Investigators. Loop diuretics in acute decompensated heart failure: necessary?
- 473 Evil? A necessary evil? Circ Heart Fail. 2009;2:56–62.
- 14. Nakano I, Tsuda M, Kinugawa S, Fukushima A, Kakutani N, Takada S, Yokota
- T. Loop diuretic use is associated with skeletal muscle wasting in patients with heart
- 476 failure. *J Cardiol*. 2020;76:109–114.
- 477 15. Nakano Y, Mandai S, Genma T, Akagi Y, Fujiki T, Ando F, Susa K, Mori T,
- 478 Iimori S, Naito S, et al. Nationwide mortality associated with perioperative acute
- dialysis requirement in major surgeries. *Int J Surg.* 2022;104:106816.
- 480 16. Isogai T, Yasunaga H, Matsui H, Tanaka H, Horiguchi H, Fushimi K.
- 481 Effectiveness of inferior vena cava filters on mortality as an adjuvant to antithrombotic
- 482 therapy. *Am J Med*. 2015;128:312.e23–312.e31.
- 483 17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
- 484 prognostic comorbidity in longitudinal studies: development and validation. *J Chron*
- 485 *Dis.* 1987;40:373–383.
- 486 18. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM,
- 487 Sundararajan V. Updating and validating the Charlson comorbidity index and score for

- 488 risk adjustment in hospital discharge abstracts using data from 6 countries. Am J
- 489 Epidemiol. 2011;173:676–682.
- 490 19. Bykov K, Bateman BT, Franklin JM, Vine SM, Patorno E. Association of
- 491 gabapentinoids with the risk of opioid-related adverse events in surgical patients in the
- 492 United States. *JAMA Netw Open*. 2020;3:e2031647.
- 493 20. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index, Md Stat.
- 494 *Med J.* 1965;14:61–65.
- 495 21. Kessler M, Frimat L, Panescu V, Briançon S. Impact of nephrology referral on
- 496 early and midterm outcomes in ESRD: EPidemiologie de l'insuffisance REnale
- 497 chronique terminale en Lorraine (EPIREL): results of a 2-year, prospective,
- 498 community-based study. *Am J Kidney Dis.* 2003;42:474–485.
- 499 22. Rethy LB, Feinstein MJ, Achenbach CJ, Townsend RR, Bress AP, Shah SJ,
- 500 Cohen JB. Antihypertensive class and cardiovascular outcomes in patients with HIV
- and hypertension. *Hypertension*. 2021;77:2023–2033.
- 502 23. Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M,
- 503 Chalmers J, Teo KK, Pepine CJ, Davis BR, et al. Antihypertensive treatment and risk of
- 504 cancer: an individual participant data meta-analysis. *Lancet Oncol.* 2021;22:558–570.

- Tasheva P, Vollenweider P, Kraege V, Roulet G, Lamy O, Marques-Vidal P,
- Méan M. Association between physical activity levels in the hospital setting and
- 507 hospital-acquired functional decline in elderly patients. JAMA Netw Open.
- 508 2020;3:e1920185.
- 509 25. Zhao W, Swanson SA, Ye J, Li X, Shelton JM, Zhang W, Thomas GD. Reactive
- oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin
- 511 II-dependent hypertension. *Hypertension*. 2006;48:637–643.
- 512 26. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and
- decreases circulating insulin-like growth factor I in rats through a pressor-independent
- 514 mechanism. *J Clin Invest*. 1996;97:2509–2516.
- 515 27. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, Thiene G, Battista
- Ambrosio G, Vescovo G. Beneficial effects on skeletal muscle of the angiotensin II type
- 1 receptor blocker irbesartan in experimental heart failure. *Circulation*.
- 518 2001;103:2195–2200.
- 519 28. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL,
- 520 Walston JD, Ward CW, Cohn RD. Losartan restores skeletal muscle remodeling and
- 521 protects against disuse atrophy in sarcopenia. Sci Transl Med. 2011;3:82ra37.

- 522 29. Hashimoto H, Mandai S, Shikuma S, Kimura M, Toma H, Sakaguchi Y,
- 523 Shiraishi S, Toshima N, Hoshino M, Kimura M, et al. The effect of antihypertensive
- 524 therapy on skeletal muscle mass and bone mineral density in patients with end-stage
- 525 kidney disease. *J Ren Nutr.* 2023. https://doi.org/10.1053/j.jrn.2023.10.008.
- 526 30. Steinman MA, Zullo AR, Lee Y, Daiello LA, Boscardin WJ, Dore DD, Gan S,
- 527 Fung K, Lee SJ, Komaiko KD, et al. Association of β-blockers with functional
- 528 outcomes, death, and rehospitalization in older nursing home residents after acute
- myocardial infarction. JAMA Intern Med. 2017;177:254–262.
- 530 31. Palau P, Seller J, Domínguez E, Sastre C, Ramón JM, de La Espriella R, Santas
- 531 E, Miñana G, Bodí V, Sanchis J, et al. Effect of β-blocker withdrawal on functional
- 532 capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol.
- 533 2021;78:2042–2056.
- 32. Mandai S, Koide T, Fujiki T, Mori Y, Ando F, Susa K, Mori T, Iimori S, Naito
- 535 S, Sohara E, et al. Association of Admission functional status and body mass index with
- mortality in patients receiving chronic dialysis: A nationwide observational cohort study.
- 537 JMA J. 2023;6:404–413.

- 538 33. Pandey, A, Kitzman, D, Reeves, G. Frailty is intertwined with heart failure:
- mechanisms, prevalence, prognosis, assessment, and management. J Am Coll Cardiol
- 540 HF. 2019;7:1001–1011.
- 541 34. Kulmala J, Nykänen I, Hartikainen S. Frailty as a predictor of all-cause mortality
- in older men and women. Geriatr Gerontol Int. 2014;14:899–905.
- 543 35. Brummel NE, Bell SP, Girard TD, Pandharipande PP, Jackson JC, Morandi A,
- Thompson JL, Chandrasekhar R, Bernard GR, Dittus RS, et al. Frailty and Subsequent
- 545 Disability and Mortality among Patients with Critical Illness. Am J Respir Crit Care
- 546 *Med*. 2017;196:64–72.
- 547 36. Kojima G, Iliffe S, Taniguchi Y, Shimada H, Rakugi H, Walters K. Prevalence
- of frailty in Japan: a systematic review and meta-analysis. *J Epidemiol*.
- 549 2017;27:347–353.
- 550 37. Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H.
- Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J
- 552 Epidemiol. 2017;27:476–482.
- 553 38. Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical
- challenge in Asia. *Hypertens Res.* 2015;38:227–236.

39. Ding Q, Zhang Z, Liu H, Nie H, Berguson M, Goldhammer JE, Young N, Boyd
 D, Morris R, Sun J. Perioperative use of renin-angiotensin system inhibitors and
 outcomes in patients undergoing cardiac surgery. *Nat Commun.* 2019;10:4202.
 558

560 **Tables**

561

562

Table 1. Characteristics of patients aged 50 years and older undergoing major

surgeries

	Treatment with	
	antihypertensive	No treatment (n =
	medications ($n = 473,327$)	376,583)
Age (year)	76 (69–82)	70 (63–78)
Female	230417 (49)	187556 (50)
BMI (kg/m^2)	23.4 (20.9–26.0)	22.5 (20.2–24.9)
Barthel Index score		
0–25	82671 (17)	45681 (12)
30–55	23467 (5)	14150 (4)
60–85	24738 (5)	14592 (4)
90–100	342451 (72)	302160 (80)
Cardiovascular disease	82490 (17)	22696 (6)
Diabetes mellitus	123050 (26)	55841 (15)
Chronic kidney disease	25046 (5)	6468 (2)
Emergency admission	134369 (28)	91961 (24)
Major surgeries		
GABG	19617 (4)	167 (0.04)
Lobectomy	37348 (8)	36642 (10)
Orthopedic surgery	212501 (45)	138757 (37)
Surgery for diseases of liver, gall		
bladder, and pancreas	64788 (14)	63543 (17)
Gastrointestinal resection and		
esophagectomy	93624 (20)	95305 (25)
Urological surgery	45449 (10)	42169 (11)
Antihypertensive class		
One class	225731 (48)	NA
Two classes	172141 (36)	NA
Three classes	58456 (12)	NA
≥Four classes	16999 (4)	NA
Thiazide and thiazide-like	24625 (5)	NA

diuretics		
CCBs	359461 (76)	NA
RASis	258134 (55)	NA
MRA	45190 (10)	NA
Beta blockers	105011 (22)	NA
Alpha blockers	22981 (5)	NA
Loop diuretics	91085 (19)	21782 (6)
Year		
2018	247059 (52)	197997 (53)
2019	226268 (48)	178586 (47)

- Data are presented as number (percentage) or median (interquartile range).
- 564 BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel
- blocker; MRA, mineral corticoid receptor antagonist; RASi,

renin–angiotensin–aldosterone system inhibitor; NA, not applicable.

Table 2. Number of antihypertensive classes and risk for mortality or functional

decline after survival in patients undergoing major surgeries.

	n/N	Model 1	Model 2	Model 3	Model 4	
No antihypertensive	25207/376583	Reference	Reference	Reference	Reference	
drugs	232017370303	Reference	Reference	Reference	Reference	
One class	22063/225731	1.20 (1.18–1.23)	1.20 (1.17–1.22)	1.17 (1.14–1.19)	1.12 (1.10–1.14)	
Two classes	17558/172141	1.23 (1.20–1.25)	1.20 (1.18–1.23)	1.14 (1.12–1.17)	1.14 (1.04–1.09)	
Three classes	6861/58456	1.42 (1.38–1.47)	1.42 (1.38–1.46)	1.30 (1.26–1.34)	1.11 (1.08–1.15)	
≥Four classes	2225/16999	1.57 (1.49–1.65)	1.58 (1.50–1.67)	1.43 (1.36–1.51)	1.12 (1.07–1.19)	

- Model 1: Adjusted for age, sex, and type of major surgeries (CABG, thoracic lobectomy,
- orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and
- urological surgery)

568

569

- Model 2: Model 1 plus BMI and Barthel Index score on admission.
- Model 3: Model 2 plus DM, CVD, CKD, emergency admission, and admission year.
- 575 Model 4: Model 3 plus loop diuretics.
- 576 CABG, coronary artery bypass grafting; BMI, body mass index; DM, diabetes mellitus;
- 577 CVD, cardiovascular disease; CKD, chronic kidney disease; CI, confidence interval;
- 578 OR, odds ratio.

579

Table 3. Combinations of antihypertensive classes and perioperative outcomes

581 following major surgeries in Japanese adults.

580

		Composite outcome		Death		Functional decline	
		OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
One class							
	TH	Reference		Reference		Reference	
	CCB	0.89 (0.73-1.08)	0.2	0.91 (0.55–1.53)	0.7	0.88 (0.72–1.08)	0.2
	RASi	0.77 (0.63-0.93)	0.008	0.58 (0.34-0.99)	0.044	0.79 (0.64–0.97)	0.022
	MRA	1.11 (0.91–1.36)	0.3	1.49 (0.88–2.51)	0.1	0.95 (0.76–1.18)	0.6
	β-blockers	1.14 (0.92–1.42)	0.2	0.59 (0.31–1.12)	0.1	1.27 (1.01–1.60)	0.040
	α-blockers	1.10 (0.90-1.34)	0.4	1.60 (0.95–2.69)	0.1	0.99 (0.80-1.22)	0.9
Two c	<u>lasses</u>						
	TH/CCB	Reference		Reference		Reference	
	TH/RASi	0.68 (0.60-0.77)	< 0.001	0.20 (0.09-0.41)	< 0.001	0.76 (0.67–0.86)	< 0.001
	CCB/RASi	0.78 (0.75–0.82)	< 0.001	0.47 (0.41–0.52)	< 0.001	0.85 (0.81-0.89)	< 0.001
	RASi/other	0.80 (0.75-0.86)	< 0.001	0.75 (0.65–0.87)	< 0.001	0.84 (0.78-0.90)	< 0.001
	Other/other	1.13 (1.03–1.23)	0.010	1.15 (0.99–1.34)	0.07	1.01 (0.90–1.12)	0.9
Three	classes						
	TH/CCB/other	Reference		Reference		Reference	
	TH/CCB/RASi	0.72 (0.49-0.82)	< 0.001	0.43 (0.31–0.60)	< 0.001	0.79 (0.70-0.89)	< 0.001
	TH/RASi/other	0.87 (0.49–1.12)	0.2	0.62 (0.36–1.07)	0.09	0.98 (0.79-1.22)	0.9
	CCB/RASi/other	0.82 (0.52-0.86)	< 0.001	0.75 (0.63–0.89)	0.001	0.88 (0.80-0.97)	0.011
	RASi/others	0.78 (0.50–1.65)	< 0.001	0.55 (0.43-0.70)	< 0.001	0.91 (0.79–1.05)	0.2
	Others	1.66 (1.02–2.69)	0.040	0.72 (0.28–1.81)	0.5	2.19 (1.29–3.72)	0.004
<u>≥Four classes</u>							
	TH/CCB/others	Reference		Reference		Reference	
	TH/CCB/RASi/ot	0.62 (0.40, 0.02)	0.001	0.55 (0.26, 0.86)	0.000	0.75 (0.55, 1.02)	0.07
her		0.63 (0.49–0.82)	0.001	0.55 (0.36–0.86)	0.008	0.75 (0.55–1.03)	0.07
	TH/RASi/others	0.74 (0.49–1.12)	0.2	0.58 (0.27–1.23)	0.2	0.90 (0.56-1.45)	0.7
	CCB/RASi/others	0.67 (0.52–0.86)	0.002	0.50 (0.34-0.76)	0.001	0.83 (0.62–1.13)	0.2
	RASi/others	0.91 (0.50–1.65)	0.8	0.55 (0.18–1.65)	0.3	1.25 (0.64–2.46)	0.5

Multivariate logistic regression models adjusted for age, sex, type of major surgeries (CABG, thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery), BMI, Barthel Index score on admission, DM, CVD, CKD, emergency admission, admission year, and loop diuretics. CABG, coronary artery bypass grafting; BMI, body mass index; DM, diabetes mellitus; CVD, cardiovascular disease; CKD, chronic kidney disease; CI, confidence interval; OR, odds ratio; CCB, calcium channel blocker; MRA, mineral corticoid receptor antagonist; RASi, renin–angiotensin–aldosterone system inhibitor; TH, thiazide/thiazide-like diuretics.

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607


608

609

Figure legends Figure 1. Antihypertensive classes and prevalence of postoperative death or functional decline after survival among patients undergoing major surgeries. a, b. prevalence of all-cause inhospital deaths (a) and functional decline (b) among nonusers and users of one, two, three, or four or more antihypertensive classes according to age category. Functional decline was defined as a ≥5-point decreased in the Barthel Index score between admission and discharge. Each spot represents a mean, whereas the solid lines represent the corresponding 95% CI. CI, confidence interval; n/N, number of events/number of participants. Figure 2. Association between surgery type and effects of antihypertensive classes on postoperative outcomes among patients with hypertension. Multivariable logistic regression models adjusted for age, sex, number of antihypertensive classes, BMI, Barthel Index score on admission, DM, CVD, CKD, emergency admission, year, and loop diuretics according to surgery type. The type of major surgeries included CABG, thoracic lobectomy, orthopedic surgery, hepatopancreatobiliary surgery, gastrointestinal resection, and urological surgery. CABG, coronary artery bypass grafting; BMI, body mass index; DM, diabetes mellitus; CVD, cardiovascular disease; CKD, chronic kidney disease; CI, confidence interval; OR, odds ratio; CCB, calcium channel blocker; MRA,

- 610 mineral corticoid receptor antagonist; RASi, renin-angiotensin-aldosterone system
- 611 inhibitor.

37



Drug class vs other comparisons	Treatment group (n/N)	Control group (n/N)			OR (95% CI)
Thiazide vs other CABG Thoracic lobectomy Orthopedic surgery Hepatopancreatobiliary surgery Gastrointestinal resection Urological surgery	186/1308 64/1642 1921/12465 163/2818 358/4058 104/2334	2125/18309 1571/35706 29095/200036 3157/61970 7888/89566 2075/43115		_ -	1.29 (1.08–1.54) 0.74 (0.56–0.97) 0.98 (0.92–1.03) 0.99 (0.82–1.18) 0.86 (0.76–0.98) 0.85 (0.68–1.07)
CCB vs other CABG Thoracic lobectomy Orthopedic surgery Hepatopancreatobiliary surgery Gastrointestinal resection Urological surgery	1980/16639 1194/28487 23461/161680 2452/48244 5856/70469 1625/33942	331/2978 441/8861 7555/50821 868/16544 2390/23155 554/11507	■ _	‡ •	1.30 (1.13–1.50) 1.30 (1.13–1.50) 0.97 (0.94–1.00) 1.08 (0.99–1.18) 0.95 (0.89–1.00) 1.09 (0.97–1.21)
RASi vs other CABG Thoracic lobectomy Orthopedic surgery Hepatopancreatobiliary surgery Gastrointestinal resection Urological surgery	1290/11714 843/20334 17192/118685 1535/33329 3565/46994 1179/27078	1021/7903 792/17014 13824/93816 1785/31459 4681/46630 1000/18371		-	0.97 (0.86–1.10) 0.72 (0.63–0.82) 0.87 (0.84–0.90) 0.69 (0.63–0.76) 0.67 (0.63–0.71) 0.83 (0.74–0.93)
MRA vs other CABG Thoracic lobectomy Orthopedic surgery Hepatopancreatobiliary surgery Gastrointestinal resection Urological surgery	1238/11619 166/1536 2600/14316 851/8683 1419/7018 183/2018	1073/7998 1469/35812 28416/198185 2469/56105 6827/86606 1996/43431	-	÷ +	0.93 (0.83–1.06) 1.21 (0.99–1.47) 1.19 (1.13–1.26) 1.33 (1.21–1.47) 1.32 (1.22–1.43) 1.06 (0.88–1.28)
α-Blocker vs other CABG Thoracic lobectomy Orthopedic surgery Hepatopancreatobiliary surgery Gastrointestinal resection Urological surgery	120/803 60/1143 1980/12339 162/2250 478/4088 152/2358	2191/18814 1575/36205 29036/200162 3158/62538 7768/89536 2027/43091		+ + + +	1.16 (0.93–1.43) 1.07 (0.8–1.43) 1.18 (1.12–1.25) 1.12 (0.94–1.35) 1.20 (1.07–1.34) 1.17 (0.96–1.42)
β-Blocker vs other CABG Thoracic lobectomy Orthopedic surgery Hepatopancreatobiliary surgery Gastrointestinal resection Urological surgery	1900/17235 551/7998 6120/37443 868/12546 2638/20388 525/9401	411/2382 1084/29350 24896/175058 2452/52242 5608/73236 1654/36048	-=-	- - -	0.77 (0.67–0.89) 1.49 (1.32–1.69) 1.08 (1.04–1.12) 1.03 (0.94–1.14) 1.32 (1.24–1.40) 1.08 (0.96–1.22)
			0.5 1.0	2.0 Favors higher ris	k